capital · May 15, 2026
Alphabet's Isomorphic Labs Secures $2.1 Billion Series B for AI Drug Design Expansion
Share the canonical public link.
Isomorphic Labs completed a $2.1 billion Series B funding round on May 12, 2026, led by Thrive Capital. Existing investors Alphabet and GV joined alongside new participants MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The investment follows a $600 million round in 2025 and supports development of the IsoDDE engine for multi-modal drug design across therapeutic areas. Partnerships with Novartis, Eli Lilly, and Johnson & Johnson include milestone payments totaling $600 million tied to clinical progress. Demis Hassabis leads the London-based firm, which originated from DeepMind's AlphaFold project in 2021.
Failed after 3 attempts. Last error: Service unavailable